William Blair Has Positive Outlook for AXSM Q2 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at William Blair raised their Q2 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, May 5th. William Blair analyst M. Minter now forecasts that the company will earn ($0.99) per share for the quarter, up from their previous forecast of ($1.31). William Blair has a "Outperform" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($3.35) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.60 EPS, Q4 2026 earnings at $1.27 EPS, FY2026 earnings at $1.64 EPS and FY2027 earnings at $12.93 EPS.

AXSM has been the subject of a number of other research reports. Truist Financial increased their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Royal Bank of Canada upped their target price on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a research note on Tuesday, April 29th. Needham & Company LLC reissued a "buy" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Bank of America lifted their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Jefferies Financial Group initiated coverage on Axsome Therapeutics in a research note on Monday, April 7th. They set a "buy" rating and a $200.00 price objective on the stock. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $172.14.

Axsome Therapeutics Stock Down 1.0 %

AXSM stock traded down $1.10 during trading on Thursday, reaching $107.76. The stock had a trading volume of 435,267 shares, compared to its average volume of 682,708. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The firm has a fifty day moving average price of $112.01 and a 200 day moving average price of $104.59. The company has a market capitalization of $5.31 billion, a P/E ratio of -17.99 and a beta of 0.46. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds have recently made changes to their positions in AXSM. Assenagon Asset Management S.A. grew its position in Axsome Therapeutics by 16,852.7% in the first quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock worth $73,176,000 after buying an additional 623,717 shares during the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the fourth quarter worth $39,767,000. Lazard Asset Management LLC lifted its holdings in shares of Axsome Therapeutics by 525.7% during the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after purchasing an additional 451,737 shares during the last quarter. Norges Bank purchased a new position in Axsome Therapeutics in the 4th quarter worth about $34,100,000. Finally, BVF Inc. IL raised its holdings in Axsome Therapeutics by 32.7% during the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock worth $117,444,000 after buying an additional 342,064 shares during the period. Institutional investors and hedge funds own 81.49% of the company's stock.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.30% of the stock is owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.